Alnylam to Webcast Presentation at the Bank of America Healthcare Conference 2006
Posted on: Thursday, 11 May 2006, 18:02 CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Bank of America Healthcare Conference 2006 on Wednesday, May 17, 2006 at 10:00 a.m. PT (1:00 p.m. ET) at The Four Seasons Hotel in Las Vegas, Nevada.
A live audio webcast of this presentation will be available on the "Investors" section of the company's website, www.alnylam.com. A replay of the presentation will be posted on the Alnylam website approximately three hours after the event, and will be archived for 30 days.
About Alnylam
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus (RSV) infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, and Novartis. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach, Germany. Alnylam is honored to be the 'emerging/mid-cap' company recipient of the 2006 James D. Watson Helix Award, the biotechnology industry's award for outstanding achievement. For more information, please visit www.alnylam.com.
Source: Business Wire
Related Articles
- PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
- Pari's Electronic Nebulizer Delivers Alnylam's RNAi Therapeutic
- PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
- Alnylam and Collaborators Present Pre-Clinical Data for RNAi Therapeutics for the Treatment of Respiratory Diseases Including Pandemic Influenza; Results Include Data on Anti-Viral Activity of RNAi Therapeutics Toward H5N1 Virus
- Alnylam Obtains Rights to RNAi Delivery Technology From The CBR Institute; Delivery Technology to Extend Alnylam's Leading Platform for RNAi Therapeutics
- Alnylam Reports Phase I Clinical Safety Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of RSV Infection; Results Reported at the 2006 Pediatric Academic Societies' Annual Meeting
- Alnylam To Collaborate With United States Army on RNAi Therapeutics for Biodefense Threats
- Alnylam Announces Product and Business Goals for 2006; Aims to Advance RNAi Therapeutic Clinical Pipeline, Execute on Strategic Alliances, and Build on Intellectual Property and Scientific Leadership Positions
- Alnylam Submits IND Application for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection; Represents First RNAi Therapeutic for Viral Infectious Diseases and Alnylam's Lead Clinical-Stage Program
- Alnylam Pharmaceuticals Initiates RNAi Therapeutic Development Program for Respiratory Syncytial Virus Infection
 |
 |
User Comments (0)
RSS Feeds